Regeneron Antibodies Prevent Symptomatic COVID-19 In Interim Phase III Data

Efficacy Data On Casirivimab/Imdevimab In Mutant Strains Forthcoming

The company said data show a lower overall infection rate and no symptomatic infections among participants receiving the drug, compared with placebo.

Antibodies immunoglobulins attacking coronavirus covid-19 influenza virus cell, 3D immune system medical illustration background. Corona virus 2019-ncov sars cell, igm. Coronavirus sars-cov-2 disease — Interim data from Regeneron's Phase III study show its antibody cocktail is effective at preventing symptomatic COVID-19. • Source: Shutterstock

Regeneron Pharmaceuticals, Inc.'s two-antibody cocktail treatment for COVID-19 could potentially present a therapeutic option for people with compromised immune systems living with those who are infected, based on interim Phase III data the company announced on 26 January showing that it reduced symptomatic infections.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Stock Watch: Dollar Weakness, Tariffs, Biosimilars In J&J’s Q1 Mix

22 Apr 2025

• By Andy Smith

Announcing increased full-year earnings guidance and another dividend increase, Johnson & Johnson’s stock price weakened, outweighed by concerns about the replacement of Stelara revenues and possible drug import tariffs.

In Brief: US FDA Rejects Regeneron’s Bid to Extend Eylea HD Dosing

22 Apr 2025

• By Sushmita Panda

Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.